CoChat

AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer

Nolan-Stevaux, Olivier, Li, Cong, Liang, Lingming, Zhan, Jinghui, Estrada, Juan, Osgood, Tao, Li, Fei, Zhang, Hanzhi, Case, Ryan, Murawsky, Christopher M., Estes, Bram, Moore, Gregory L., Bernett, Matthew J., Muchhal, Umesh, Desjarlais, John R., Staley, Binnaz K., Stevens, Jennitte, Cooke, Keegan S., Aeffner, Famke, Thomas, Oliver, Stieglmaier, Julia, Lee, Jae-Lyun, Coxon, Angela, Bailis, Julie M. · 2024 · Cancer Discovery
Cited by 55

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic castration-resistant prostate cancer (mCRPC). We developed a STEAP1-targeted XmAb 2+1 T-cell engager (TCE) molecule, AMG 509 (also designated xaluritamig), that is designed to redirect T cells to kill prostate cancer cells that express STEAP1. AMG 509 mediates potent T cell–dependent cytotoxicity of prostate cancer cell lines in vitro and promotes tumor regression in xenograft and syngeneic mouse models of prostate cancer in vivo. The avidity-driven activity of AMG 509 enables selectivity for tumor cells with high STEAP1 expression compared with normal cells. AMG 509 is the first STEAP1 TCE to advance to clinical testing, and we report a case study of a patient with mCRPC who achieved an objective response on AMG 509 treatment. Significance: Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets. AMG 509 provides a targeted immunotherapy approach to engage a patient's T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Kelly et al., p. 76. This article is featured in Selected Articles from This Issue, p. 5

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-0984

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 55

Metadata

Authors
Nolan-Stevaux, O., Li, C., Liang, L., Zhan, J., Estrada, J., Osgood, T., Li, F., Zhang, H., Case, R., Murawsky, C. M., Estes, B., Moore, G. L., Bernett, M. J., Muchhal, U., Desjarlais, J. R., Staley, B. K., Stevens, J., Cooke, K. S., Aeffner, F., Thomas, O., Stieglmaier, J., Lee, J.-L., Coxon, A., & Bailis, J. M.
Venue
Cancer Discovery
Published
2023-10-20
Volume
14
Issue
1
Pages
90-103
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4387797966
Cited by
55
References
9
FWCI
8.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.